Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 3/20 | 0.71 |
| ▸ | DHODH | Q02127 | 1/20 | 0.69 |
| ▸ | FABP4 | P15090 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | FTO | Q9C0B1 | 4/20 | 0.56 |
| ▸ | FABP3 | P05413 | 3/20 | 0.56 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.55 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.54 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28133218 | 0.87 | FABP4 (0.75) | TTRFABP4FTOFABP3FABP5 | |
| SCHEMBL3681838 | 0.87 | NPC1 (0.71) | TTRDHODHFABP4KDM4ENPC1 | |
| SCHEMBL6484216 | 0.86 | FTO (0.64) | TTRDHODHFABP4FTOFABP3 | |
| SCHEMBL16489003 | 0.84 | CTSV (0.58) | TTRDHODHFABP4MEN1KMT2A | |
| SCHEMBL4246580 | 0.84 | FABP4 (0.71) | TTRDHODHFABP4RAB9AFTO | |
| SCHEMBL3428200 | 0.83 | TTR (1.00) | TTRFABP4KDM4ENPC1RAB9A | |
| SCHEMBL6481893 | 0.82 | MEN1 (0.74) | TTRDHODHFABP4FTOFABP3 | |
| SCHEMBL11983339 | 0.82 | DHODH (1.00) | DHODHKDM4ENPC1RAB9AMEN1 | |
| SCHEMBL24021600 | 0.81 | FTO (0.77) | TTRFTOCLCN2 | |
| SCHEMBL18109767 | 0.81 | FABP4 (0.85) | TTRFABP4FABP3FABP5MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| EP-4214189-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL Business Ltd (GB) | 2023-07-26 | — | — | EP | disclosed |
| US-20220184041-A1 | (AZA)Benzothiazolyl Substituted Pyrazole Compounds | PFIZER INC. (US) | 2022-06-16 | — | — | US | disclosed |
| WO-2022112919-A1 | (AZA)BENZOTHIAZOLYL SUBSTITUTED PYRAZOLE COMPOUNDS | PFIZER INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022058733-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS PLC (GB) | 2022-03-24 | — | — | WO | disclosed |
| WO-2020128816-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS COMPRISING A COMBINATION OF A BENZOXAZOLE TRANSTHYRETIN STABILIZER AND AN ADDITIONAL THERAPEUTIC AGENT | PFIZER INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20120309835-A1 | METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES | REVISION THERAPEUTICS, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120288568-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA SERUM RETINOL, SERUM RETINOL BINDING PROTEIN (RBP), AND/OR SERUM RETINOL-RBP MODULATION | REVISION THERAPEUTICS, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120202885-A1 | METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES | REVISION THERAPEUTICS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8236984-B2 | Compound and use thereof in the treatment of amyloidosis | PENTRAXIN THERAPEUTICS LTD. (GB) | 2012-08-07 | — | — | US | disclosed |
| EP-1904043-A2 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA SERUM RETINOL, SERUM RETINOL BINDING PROTEIN (RBP), AND/OR SERUM RETINOL-RBP MODULATION | Sirion Therapeutics, Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| EP-1827407-A2 | METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES | Sirion Therapeutics, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1820501-A1 | Therapeutic agent for depletion of an unwanted protein population from plasma | Pentraxin Therapeutics Limited (GB) | 2007-08-22 | — | — | EP | disclosed |
| US-20070098631-A2 | DIAGNOSTIC COMPOUNDS COMPRISING A SCAFFOLD COUPLED TO A SIGNAL ENTITY FOR MEDICAL IMAGING DIAGNOSTIC | GUERBET (FR) | 2007-05-03 | — | — | US | disclosed |
| US-20070098631-A2 | DIAGNOSTIC COMPOUNDS COMPRISING A SCAFFOLD COUPLED TO A SIGNAL ENTITY FOR MEDICAL IMAGING DIAGNOSTIC | GUERBET (FR) | 2007-05-03 | — | — | US | disclosed |
| US-20070015827-A1 | Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation | SYTERA, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| WO-2007008821-A2 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA SERUM RETINOL, SERUM RETINOL BINDING PROTEIN (RBP), AND/OR SERUM RETINOL-RBP MODULATION | SIRION THERAPEUTICS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| US-20060135460-A1 | Methods, assays and compositions for treating retinol-related diseases | SYTERA, INC. (US) | 2006-06-22 | — | — | US | disclosed |
| WO-2006063128-A2 | METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES | SIRION THERAPEUTICS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| WO-2003013508-A1 | THERAPEUTIC AGENT FOR DEPLETION OF AN UNWANTED PROTEIN POPULATION FROM PLASMA | PENTRAXIN THERAPEUTICS LIMITED (GB) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120288568-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA SERUM RETINOL, SERUM RETINOL BINDING PROTEIN (RBP), AND/OR SERUM RETINOL-RBP MODULATION | RBP1, RBP4, ALDH1A2 | TTR 25/4885DHODH 1756/4885FABP4 37/4885 |
| US-20070098631-A2 | DIAGNOSTIC COMPOUNDS COMPRISING A SCAFFOLD COUPLED TO A SIGNAL ENTITY FOR MEDICAL IMAGING DIAGNOSTIC | HTR3D, BRD4, CNR1 | TTR 4661/4885DHODH 1476/4885FABP4 3657/4885 |
| US-20120309835-A1 | METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES | RBP1, RBP4, TTR | TTR 3/4885DHODH 961/4885FABP4 43/4885 |
| US-20060135460-A1 | Methods, assays and compositions for treating retinol-related diseases | RBP1, RBP4, TTR | TTR 3/4885DHODH 961/4885FABP4 43/4885 |
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | TTR, C1R, APOB | TTR 1/4885DHODH 3273/4885FABP4 1269/4885 |
| US-20070015827-A1 | Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation | RBP1, RBP4, ALDH1A2 | TTR 25/4885DHODH 1756/4885FABP4 37/4885 |
| US-20220184041-A1 | (AZA)Benzothiazolyl Substituted Pyrazole Compounds | TTR, APOB, SERPINB6 | TTR 1/4885DHODH 1851/4885FABP4 2203/4885 |
| US-20120202885-A1 | METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES | RBP1, RBP4, TTR | TTR 3/4885DHODH 961/4885FABP4 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.